Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 207127 + faldaprevir + ribavirin in treatment-naive genotype 1 chronic hepatitis C
2012-003535-27Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deleobuvir, faldaprevir and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained virologic response at 12 weeks post-treatment. Started Sep 2012; status: completed.
02
Drugs
deleobuvirfaldaprevirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2012-003535-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003535-27.